You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps

    SBC: Contech Medical, Inc.            Topic: NICHD

    Project Summary Abstract We propose a new approach to the decontamination of central venous catheters and the prevention of central line associated bloodstream infectionsCLABSIan important healthcare associated infectionCLABSIs cost the US healthcare system approximately $billion annuallyPronovostNEJMAdditionallyCLABSIs can be life threateningespecially in the very young and critically illEven whe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Caring for the Caregiver: A Theory-Driven Mobile Intervention to Promote Caregiver Well-Being

    SBC: Pro-Change Behavior Systems Inc            Topic: NIA

    Overmillion Americans are currently providing unpaid care to a family memberrelativeor friend with Alzheimer s disease or related dementiaWhile caregiving can be a positive experience that brings meaning and an increased sense of purposeit can also take a tollNearlyof Alzheimer s and dementia caregivers rate their emotional distress as high or very highand as many assuffer from depressionCaregiver ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, LLC            Topic: R

    The primary goal of this proposed research is to develop a rapid point of care test that assesses the risk of neonatal sepsisNSand or necrotizing enterocolitisNECin infants based on Inter alpha inhibitor proteinsIAIPlevels in bloodThe test is expected to be simpleuser friendlyportable and suitable for use in the NICUNS and NEC are associated with high mortality and morbidityincluding adverse neuro ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Galectin-1 Protein Therapy for Congenital Muscular Dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    Abstract Lamininrelated congenital muscular dystrophyLAMACMDalso known as Merosin Deficient Congenital Muscular DystrophyMDC Ais a fatal muscle wasting disease that affects patients from birthLAMACMD results from mutations in the LAMAgene resulting in loss of lamininproteinLamininis required for the formation of the heterotrimers lamininand lamininwhich are major constituents of the skeletal and c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients

    SBC: EPIVAX, INC.            Topic: 999

    Abstract SignificanceInfantile Pompe DiseaseIPDis an autosomal recessive glycogen storage disorder caused by a deficiency of acid alpha glucosidaseGAAleading to accumulation of glycogen in lysosomesprimarily in skeletalcardiac and smooth musclesUntreated IPD infants die within the firstyears of lifeEnzyme replacement therapyERTwith recombinant human GAArhGAAimproves survival and quality of lifebut ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Combining Next-Generation Sequencing and Advanced Algorithms to Elucidate Tumor Heterogeneity

    SBC: Medley Genomics            Topic: 100

    PROJECT SUMMARY Cancer is one of the leading causes of morbidity and mortality worldwideDriven by advancements in quantifying and characterizing the molecular profile of the tumorcancer therapy is becoming more personalizedselectiveand specificA key factor contributing to the lethalitytherapeutic failureand drug resistance of cancer patientshoweveris intra tumor heterogeneityITHcharacterized by a ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A cost-effective robotic platform for on-demand production of flexibly dosed medications in a chewable gummy dosage form

    SBC: Vitae Industries, Inc.            Topic: NICHD

    PROJECT SUMMARYThis project s goal is to develop an innovative cost effective robotic platform for fast on demand pharmacy production of pediatric drugs as individually tailored palatable gummy dosage formsMedication adherence is notoriously low among children due to difficulty swallowing pills and rejection of bad tasting medicationsAlthough some common pediatric drugs have flavored liquid formsp ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Stage-Based Mobile Intervention for Substance Use Disorders in Primary Care: Implementation and Cluster-Randomized Trial

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Nearlymillion Americans ageand olderneed treatment for a substance use disorderSUDWhile onlyof individuals requiring treatment for a SUD receive itan estimated two thirds see a primary care or urgent care provider everymonthsPrimary care providers are in a unique position to perform ScreeningBrief Interventionand Referral to TreatmentSBIRTWith Phase I contract fundingPro Change developed and pilot ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Calista Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government